Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trialStéphane Palfi, Kyriacos Mitrophanous, Jean Marc Gurruchaga et al.|The Lancet|2014Cited by 436
Severe COVID-19-related encephalitis can respond to immunotherapyAlbert Cao, Philippe Fossati, Clémence Marois et al.|Brain|2020Cited by 66